Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-based tacrolimus dosing after living-donor kidney transplantation
NL-OMON36822Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tacrolimus in kidney transplant and Renal Insufficiency (RI) (2 arms), sponsored by Erasmus MC. Primary endpoints: Proportion of patients reaching tacrolimus target levels on day 3 and Proportion of patients reaching tacrolimus target levels on day 7. Started Nov 2010; status: active, not recruiting.
02
Drugs
tacrolimus
03
Conditions
kidney transplantRenal Insufficiency (RI)
Beyond the preview
Go deeper on NL-OMON36822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36822.